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Mutation of human immunodeficiency virus type 1 at amino acid 585 on gp41 results in loss of killing by CD8+ A24-restricted cytotoxic T lymphocytes
There is a failure of the immune system to eliminate human immunodeficiency type 1 (HIV-1)-infected cells. It is assumed that the HIV-1-specific cytotoxic T-lymphocyte (CTL) responses help to limit virus replication by destroying virus-infected cells in vivo but eventually the infection progresses and immunodeficiency is complicated by numerous infections with opportunistic agents. There have been several reports concerning HIV-1-specific CTL which have been detected directly by using peripheral blood mononuclear cells (PBMC) of HIV-1-infected individuals (5, 9, 11, 12, 15, 16) ; therefore, there is evidence of ongoing antigenic stimulation by HIV-1-infected cells during HIV-1 infection. To learn more precisely about human T-cell responses to HIV-infected cells, we and others have attempted to clone HIV-1-specific T cells (3, 6, 13, 16) . The amount of available information which defines virus-specific T-cell epitopes at the clonal level is limited. For example, only two epitopes restricted by different major histocompatibility complex class II-restricting elements have been defined on HIV-1 gpl6O (3, 13) . Recently, our laboratory defined in detail the first CD8+ CTL epitope on gp4l, amino acids (aa) 768 to 778, which was restricted by human leukocyte antigen (HLA) A3.1 (14a) . In In this report, we describe a second CD8+ CTL epitope on gp41 which was localized to aa 584 to 591 of gp4l by using the PBMC of another HIV-1-infected donor. The clone recognized target cells expressing gp4l of the HIV-1 IIIB and MN prototype strains and also killed target cells pulsed with a synthetic peptide reflecting the sequence of the HIV-1 JRCSF strain. This clone failed to recognize target cells pulsed with peptides with a mutation from K to R or Q at aa 585 and thus failed to kill target cells expressing sequences of some prototype HIV-1 strains which have been sequenced, for example, ADA, JFL, SC, ALA1, BAL1, SF2, VRF, SF33, and WMJ2. Therefore, a mutation at aa 585 on gp41 results in nonrecognition by HLA A24-restricted CD8+ CTL.
MATERIALS AND METHODS
Recombinant vaccinia viruses. Recombinant vaccinia viruses that express four different N-terminal overlapping Env proteins of 502, 635, 747, and 851 aa of the BH8 isolate were constructed as previously described (2) . HeLa cells infected with these viruses were trypsinized, sonicated, and stored at -80°C before use.
Synthesis of peptides. Synthetic peptides of HIV-1 gpl60 (NL43 strain) were constructed as previously described (14a). Some peptides were synthesized by the RaMPS system (Du Pont, Boston, Mass.). The amino acid composition of each peptide was analyzed by using the Waters PICO TAG Amino Acid Analysis System. Envelope protein sequences and numbering of residues are based on the report of Myers et al. (8) .
Establishment of an HIV-1 env-specific CTL clone. CTL clones were generated as previously described (6 Table 1 show that the epitope lies between aa 502 and 635 on gpl60. In the same experiment, monoclonal antibodies to cross-reactive framework determinants on HLA class I (W6/32) or II (DP, DQ, and DR) were added to the assay. Significant reduction of cytotoxicity was observed only when the monoclonal antibody to HLA class I was used.
T-cell line 137 was tested on target cells pulsed with synthetic peptides based on the sequence of gp4l of HIV-1 IIIB, because line 137 killed target cells infected with vaccinia virus expressing gpl60 but not gpl20 ( Table 1) . The results shown in Table 2 CTL activity was determined at an effector-target cell ratio of 4.
peptide 84. Subclone 137.6 provided a high level of killing of both of these target cells, so it was used for characterization. Clone 137.6 was analyzed by fluorescence-activated cell sorter with monoclonal antibodies to CD3, CD4, and CD8, which revealed it to be a CD8+ clone, since all of the cells present were CD3+, CD8+, and CD4-(data not shown).
To define the epitope recognized by clone 137.6 in detail, a series of synthetic peptides representing segments contained within aa 564 to 591 were prepared. The results shown in Table 3 indicate that the epitope recognized by 137.6 and another subclone, 137.19, is contained in aa 580 and 591.
We then prepared a series of synthetic peptides with N-terminal truncations from aa 580 to 591. In addition, we synthesized peptides for the region from 580 to 591 to represent mutant virus strains at sites in this region on the basis of published sequence data on HIV-1 strains (8). The results shown in Table 4 indicate that aa 584 to 591 contained the epitope recognized by the CD8+ clone. Lysis of target cells pulsed with peptides representing mutations in the sequences of other prototype strains indicated that a change from K to R or Q at aa 585 resulted in nonrecognition by the clone. A peptide based on the sequence of JRCSF, which has a mutation at 590 from L to M, was recognized. Therefore, certain strains, such as IIIB, MN, and JRCSF, were recognized by this CD8+ CTL clone but a mutation at (13) or after immunization of an HIV-1-seronegative individual with experimental recombinant baculovirus-expressed gpl60 vaccine (10) . Following administration of the experimental vaccine, a CD4+ HLA DPw4-restricted T-cell clone was derived and mapped to a region which overlaps the epitope on gp4l detected with a CD8+ CTL clone from an infected donor described in this report (3) . There have been several reports in murine T-cell systems of specific T-cell determinants on proteins which overlap epitopes that can be presented to CD4 and CD8 T cells (14) . We have defined a highly conserved HLA Cw3-restricted CD8+ CTL epitope on HIV-1 p24 aa 140 to 148 (6) The importance of CD8+ CTL responses in HIV-1 infections remains to be determined. In the absence of an appropriate animal model, it has not been possible to test directly the effect of adoptive transfer of CTL clones specific for HIV-1. Studies with the Hu/SCID mouse model which should be of interest are being attempted. One of the major questions concerning the biology of HIV-1-specific CTL responses is their failure to eliminate HIV-1-infected cells and resolve HIV-1 infections despite evidence that virusspecific CD8+ CTL can cure T-cell-deficient mice with other virus infections (7), including persistent established lymphocytic choriomeningitis virus infection in nude mice (4) . The ability of HIV-1 and other lentiviruses to insert provirus into host cell DNA (17) , antigenic variation at T-cell epitopes such as those described in this report, and the impact of HIV-1 infections and immune responses to HIV-1-infected immunocompetent cells may contribute to the failure of human immune systems to resolve HIV-1 infections.
